Simona Vallarelli

Castellana, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study.

HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study.

Journal: ESMO gastrointestinal oncology
Published: April 17, 2026

Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study.

Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study.

Journal: European journal of cancer (Oxford, England : 1990)
Published: April 13, 2025

Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial.

Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial.

Journal: ESMO open
Published: January 20, 2025

Claudin 18.2: An attractive marker in pancreatic ductal adenocarcinoma.

Claudin 18.2: An attractive marker in pancreatic ductal adenocarcinoma.

Journal: Oncology letters
Published: July 11, 2024

Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial.

Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 28, 2024

Autotaxin-Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications.

Autotaxin-Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications.

Journal: International journal of molecular sciences
Published: May 30, 2024

VEGFA Status as a Predictive Marker of Therapy Outcome in Metastatic Gastric Cancer Patients Following Ramucirumab-Based Treatment.

VEGFA Status as a Predictive Marker of Therapy Outcome in Metastatic Gastric Cancer Patients Following Ramucirumab-Based Treatment.

Journal: Biomedicines
Published: September 06, 2023

Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door?

Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door?

Journal: Immunotherapy
Published: March 23, 2023

Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues.

Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues.

Journal: Cancers
Published: March 21, 2023

Unexpected response to palliative radiotherapy for subcutaneous metastases of an advanced small cell pancreatic neuroendocrine carcinoma: a case report of two different radiation schedules.

Unexpected response to palliative radiotherapy for subcutaneous metastases of an advanced small cell pancreatic neuroendocrine carcinoma: a case report of two different radiation schedules.

Journal: BMC cancer
Published: August 01, 2019

Adjuvant therapy of endometrial cancer: "taxane or not taxane, this is the question".

Adjuvant therapy of endometrial cancer: "taxane or not taxane, this is the question".

Journal: Translational cancer research
Published: April 24, 2019

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.

Journal: Journal of cellular physiology
Published: October 10, 2018
Showing 1-12 of 13

Last Updated: 09/26/2026